ATE464391T1 - Hyaluronidase aus menschlichem plasma - Google Patents

Hyaluronidase aus menschlichem plasma

Info

Publication number
ATE464391T1
ATE464391T1 AT97910003T AT97910003T ATE464391T1 AT E464391 T1 ATE464391 T1 AT E464391T1 AT 97910003 T AT97910003 T AT 97910003T AT 97910003 T AT97910003 T AT 97910003T AT E464391 T1 ATE464391 T1 AT E464391T1
Authority
AT
Austria
Prior art keywords
hphase
purification
discovery
methods
antibodies
Prior art date
Application number
AT97910003T
Other languages
English (en)
Inventor
Robert Stern
Gregory Frost
Anthony Csoka
Tim Wong
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/733,360 external-priority patent/US6103525A/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE464391T1 publication Critical patent/ATE464391T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01036—Hyaluronoglucuronidase (3.2.1.36)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97910003T 1996-10-17 1997-10-07 Hyaluronidase aus menschlichem plasma ATE464391T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/733,360 US6103525A (en) 1996-10-17 1996-10-17 Hybridoma cell lines producing monoclonal antibodies that bind to human plasma hyaluronidase
US08/916,935 US6193963B1 (en) 1996-10-17 1997-08-21 Method of treating tumor-bearing patients with human plasma hyaluronidase
PCT/US1997/018089 WO1998016655A1 (en) 1996-10-17 1997-10-07 Human plasma hyaluronidase

Publications (1)

Publication Number Publication Date
ATE464391T1 true ATE464391T1 (de) 2010-04-15

Family

ID=27112566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97910003T ATE464391T1 (de) 1996-10-17 1997-10-07 Hyaluronidase aus menschlichem plasma

Country Status (7)

Country Link
US (4) US6193963B1 (de)
EP (1) EP0961833B1 (de)
JP (1) JP4503708B2 (de)
AT (1) ATE464391T1 (de)
AU (1) AU730705B2 (de)
CA (1) CA2264484C (de)
WO (1) WO1998016655A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US20030212021A1 (en) * 2001-01-25 2003-11-13 Frost Gregory I. Myeloid colony stimulating factor and uses thereof
EP1325125B1 (de) 2000-07-10 2013-06-05 Board Of Regents, The University Of Texas System Tumor-unterdrückende gene des chromosoms 3p21.3
US20030228600A1 (en) * 2000-07-14 2003-12-11 Eppendorf 5 Prime, Inc. DNA isolation method and kit
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2002306821A1 (en) * 2001-03-22 2002-10-08 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
AU2003220115A1 (en) * 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR20130135986A (ko) * 2003-03-05 2013-12-11 할로자임, 아이엔씨 가용성 하이알우로니다제 당단백질 (ｓＨＡＳＥＧＰ), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
EP1616955A4 (de) * 2003-03-31 2006-08-30 Seikagaku Kogyo Co Ltd Katalysator für die spaltung von zuckerketten
US8034790B2 (en) 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
CA2603671C (en) * 2005-04-26 2012-03-27 Laboratoires Serono S.A. Insp163 polypeptides for the treatment or prevention of cancer and arthritis
PL1909973T3 (pl) 2005-07-15 2019-01-31 Micell Technologies, Inc. Polimerowe powłoki zawierające proszek leku o kontrolowanej morfologii
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
US7920926B2 (en) * 2005-12-09 2011-04-05 Apsara Medical Corporation Method and apparatus for carrying out the controlled heating of tissue in the region of dermis
EP2944382A1 (de) 2006-04-26 2015-11-18 Micell Technologies, Inc. Beschichtungen mit mehreren wirkstoffen
US20080097557A1 (en) * 2006-10-19 2008-04-24 Apsara Medical Corporation Method and apparatus for carrying out the controlled heating of tissue in the region of dermis
US9539593B2 (en) 2006-10-23 2017-01-10 Micell Technologies, Inc. Holder for electrically charging a substrate during coating
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2679712C (en) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents having biodegradable layers
WO2008100930A2 (en) * 2007-02-13 2008-08-21 Cornell University Convection enhanced delivery apparatus, method and application
WO2008148013A1 (en) 2007-05-25 2008-12-04 Micell Technologies, Inc. Polymer films for medical device coating
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
FI4269578T3 (fi) * 2008-03-06 2024-06-07 Halozyme Inc Liukoisen hyaluronidaasin suurimittainen tuotanto
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR101647932B1 (ko) 2008-04-14 2016-08-11 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
WO2009128918A1 (en) * 2008-04-14 2009-10-22 Halozyme, Inc. Combination therapy using a soluble hyaluronidase and a bisphosphonate
MX350637B (es) 2008-04-17 2017-09-11 Micell Technologies Inc Stents que tienen capas bioabsorbibles.
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2153844A1 (de) 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Humane Hyaluronidasen zum erneuten axonalen Wachstum
US20100130958A1 (en) * 2008-11-26 2010-05-27 David Kang Device and Methods for Subcutaneous Delivery of High Viscosity Fluids
SI3037529T1 (sl) 2008-12-09 2019-06-28 Halozyme, Inc. Razširjeni topni polipeptidi PH20 in njihove uporabe
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
EP2411083A4 (de) 2009-03-23 2013-11-13 Micell Technologies Inc Medizinische wirkstofffreisetzungsvorrichtung
EP2413847A4 (de) 2009-04-01 2013-11-27 Micell Technologies Inc Beschichtete stents
CA2759015C (en) 2009-04-17 2017-06-20 James B. Mcclain Stents having controlled elution
US20100305500A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
EP2453834A4 (de) 2009-07-16 2014-04-16 Micell Technologies Inc Medizinische wirkstofffreisetzungsvorrichtung
IN2012DN03219A (de) 2009-09-17 2015-10-23 Baxter Healthcare Sa
EP2531140B1 (de) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit
EP2547384A4 (de) * 2010-03-19 2014-07-23 Halozyme Inc Vorrichtung zur arzneimittelabgabe mittels gasdruck
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
MX348420B (es) 2010-07-20 2017-06-12 Halozyme Inc Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
JP6194248B2 (ja) 2010-10-28 2017-09-06 パシラ ファーマシューティカルズ インコーポレーテッド 非ステロイド性抗炎症薬の徐放性処方物
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
EP3881876A1 (de) 2011-08-01 2021-09-22 Alcyone Lifesciences, Inc. Mikrofluidische wirkstofffreisetzungsvorrichtungen
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
MX342735B (es) 2011-10-24 2016-10-07 Halozyme Inc Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
ES2609582T3 (es) 2011-12-30 2017-04-21 Halozyme, Inc. Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
BR112014024848A2 (pt) 2012-04-04 2017-07-11 Halozyme Inc terapia de combinação com um agente antihialuronano e um taxano direcionamento ao tumor
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US9919129B2 (en) 2012-12-18 2018-03-20 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
CN105307597A (zh) 2013-03-12 2016-02-03 脉胜医疗技术公司 可生物吸收的生物医学植入物
EP2996629B1 (de) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbierbare biomedizinische implantate
CN105517617B (zh) 2013-06-17 2019-06-21 亚克安娜生命科学有限公司 用于保护导管末梢的方法和装置以及用于微导管的立体定向固定装置
WO2015017609A2 (en) 2013-07-31 2015-02-05 Alcyone Lifesciences, Inc. Systems and methods for drug delivery, treatment, and monitoring
PL3186281T3 (pl) 2014-08-28 2019-10-31 Halozyme Inc Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
US10806396B2 (en) 2015-01-26 2020-10-20 Alcyone Lifesciences, Inc. Drug delivery methods with tracer
AU2017205323B2 (en) 2016-01-04 2022-01-27 Alcyone Therapeutics, Inc. Methods and devices for treating stroke
EP3541815A4 (de) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. Multivesikuläre liposomenformulierung mit zinkmeloxicamkomplex-mikropartikeln und verfahren zur herstellung davon
US12042528B2 (en) 2017-12-29 2024-07-23 The Trustees Of Columbia University In The City Of New York Hyaluronidase for the prevention, treatment, reduction and/or abolishment of cerebral edema and intracranial pressure
US11439659B2 (en) * 2018-12-03 2022-09-13 The Regents Of The University Of California Methods and compositions to prevent and treat inflammation and allergic reactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5413510B2 (de) 1973-08-28 1979-05-31
EP0263417A1 (de) 1986-09-30 1988-04-13 BIOCHEMIE Gesellschaft m.b.H. Verwendung von Hyaluronidase
DK641487A (da) 1987-12-07 1989-06-08 Gluetech Aps Fremgangsmaade til modificering af polymeroverflader
WO1996003497A1 (en) 1994-07-22 1996-02-08 Seikagaku Corporation Novel hyaluronidase
JP3657644B2 (ja) * 1995-03-30 2005-06-08 森永乳業株式会社 モノクローナル抗体及びハイブリドーマ
US5747027A (en) * 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase

Also Published As

Publication number Publication date
CA2264484C (en) 2012-02-07
AU4748297A (en) 1998-05-11
CA2264484A1 (en) 1998-04-23
AU730705B2 (en) 2001-03-15
US20030170243A1 (en) 2003-09-11
HK1021648A1 (en) 2000-06-23
WO1998016655A1 (en) 1998-04-23
EP0961833A4 (de) 2002-10-16
EP0961833B1 (de) 2010-04-14
US7781397B2 (en) 2010-08-24
US20040096921A1 (en) 2004-05-20
JP4503708B2 (ja) 2010-07-14
US6193963B1 (en) 2001-02-27
US7148201B2 (en) 2006-12-12
US7105330B2 (en) 2006-09-12
JP2001508646A (ja) 2001-07-03
EP0961833A1 (de) 1999-12-08
US20070134228A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
ATE464391T1 (de) Hyaluronidase aus menschlichem plasma
WO1998007850A3 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease and down syndrome in humans
WO1997032018A3 (en) Hepatitis c virus ribozymes
ATE266723T1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
CA2228635A1 (en) Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
ES2130177T3 (es) Tratamiento de poblaciones de celulas.
MXPA03002413A (es) Moleculas tipo b7 y uso de las mismas.
Spitsin et al. Uric acid levels in patients with multiple sclerosis: analysis in mono-and dizygotic twins
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
NO982246L (no) FremgangsmÕte til deteksjon av Ki-ras mutasjoner
Baker Signal duration as a factor in vigilance tasks
CA2281895A1 (en) Ikb kinases
EP0756488A4 (de) Tumor-suppressor-gen und verfahren zum nachweis von krebs
ATE359299T1 (de) Mutationen des menschlichen mink gens, die mit arrhytmie verbunden sind
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
AU2001282364A1 (en) Diagnosis and treatment of prostate cancer
WO1998011234A3 (en) Human protein kinases
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
WO2001042474A3 (en) Interferon-like molecules and uses thereof
AU2003225237A1 (en) Antibodies that specifically bind to chemokine beta-4
WO2000023587A3 (en) Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
WO1997042347A3 (en) 5-lipoxygenase gene polymorphisms and their use in classifying patients
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
WO2003066808A3 (en) Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
WO2003028536A3 (en) Methods for diagnosing and treating heart disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties